{"id":"NCT01885182","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","briefTitle":"Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain","officialTitle":"A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxy/Nal Prolonged Release Tablets Compared to Oxy PR in Subjects With Moderate to Severe, Chronic Cancer Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-01","primaryCompletion":"2015-08-30","completion":"2015-12-30","firstPosted":"2013-06-24","resultsPosted":"2019-09-16","lastUpdate":"2019-10-04"},"enrollment":232,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cancer","Pain"],"interventions":[{"type":"DRUG","name":"Oxycodone/Naloxone","otherNames":["Targin"]},{"type":"DRUG","name":"Oxycodone","otherNames":["OXY PR"]}],"arms":[{"label":"Oxycodone/Naloxone","type":"EXPERIMENTAL"},{"label":"Oxycodone","type":"ACTIVE_COMPARATOR"}],"summary":"To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain","primaryOutcome":{"measure":"The Change of BFI-Bowel Function Index at visit8","timeFrame":"Visit8, visit8 taking place at week 4 or after early discontinuation/withdrawal from study","effectByArm":[{"arm":"Oxycodone/Naloxone","deltaMin":48.3,"sd":25.7},{"arm":"Oxycodone","deltaMin":51.2,"sd":26.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":28,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":114},"commonTop":["Vomiting","Nausea","Fatigue","Abdominal distension","Pyrexia"]}}